Hypogonadism Stocks List
|FTXH||D||First Trust Nasdaq Pharmaceuticals ETF||2.58|
|FTXN||B||First Trust Nasdaq Oil & Gas ETF||2.58|
|XPH||D||SPDR S&P Pharmaceuticals ETF||2.17|
|PJP||D||PowerShares Dynamic Pharmaceuticals||2.03|
|PILL||F||Direxion Daily Pharmaceutical & Medical Bull 3X Shares||1.56|
View all Hypogonadism related ETFs...
Hypogonadism means diminished functional activity of the gonads—the testes or the ovaries—that may result in diminished production of sex hormones.
Low androgen (e.g., testosterone) levels are referred to as hypoandrogenism and low estrogen (e.g., estradiol) as hypoestrogenism. These are responsible for the observed signs and symptoms. Hypogonadism can decrease other hormones secreted by the gonads including progesterone, DHEA, anti-Müllerian hormone, activin, and inhibin. Sperm development (spermatogenesis) and release of the egg from the ovaries (ovulation) may be impaired by hypogonadism, which, depending on the degree of severity, may result in partial or complete infertility.
In January 2020, the American College of Physicians issued clinical guidelines for testosterone treatment in adult men with age-related low levels of testosterone. The guidelines are supported by the American Academy of Family Physicians. The guidelines include patient discussions regarding testosterone treatment for sexual dysfunction; annual patient evaluation regarding possible notable improvement and, if none, to discontinue testosterone treatment; physicians should consider intramuscular treatments, rather than transdermal treatments, due to costs and since the effectiveness and harm of either method is similar; and, testosterone treatment for reasons other than possible improvement of sexual dysfunction may not be recommended.